(Q74063684)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference

1 reference

D V Gold

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

T Cardillo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

D M Goldenberg

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

R M Sharkey

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 July 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

Critical Reviews in Oncology Hematology

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

147-154

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Treatment of cancer of the pancreas by precision high dose (PHD) external photon beam and intraoperative electron beam therapy (IOEBT).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Comparison of therapeutic efficacy and host toxicity of two different 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Radioimmunodetection with 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Preoperative clinical radioimmunodetection of pancreatic cancer by 111 In-labeled chimeric monoclonal antibody Nd2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Assessment of disseminated pancreatic cancer: a comparison of traditional exploratory laparotomy and radioimmunoguided surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Single-chain antibodies in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Biodistribution of murine and chimeric Fab fragments of the monoclonal antibody A7 in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Generation and application of monoclonal antibody to human pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

The usefulness of serial changes in serum CA19-9 levels in the diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Comparative study of carbohydrate antigen 195 and carcinoembryonic antigen for the diagnosis of pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Expression of mucin antigens in human cancers and its relationship with malignancy potential

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Pancreatic tumour marker anti-mucin antibody CAM 17.1 reacts with a sialyl blood group antigen, probably I, which is expressed throughout the human gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Radioimmunotherapy for pancreatic carcinoma using (131)I-labeled monoclonal antibody Nd2 in xenografted nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

Radioimmunodetection of colorectal cancer metastases with 131I-labeled monoclonal antibody B72.3: a pilot study to determine efficacy of detection and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900114-7

7 January 2021

10.1016/S1040-8428(01)00114-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11418312%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference